Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03789968 · ClinicalTrials.gov registry record
The Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experienced Patients
A clinical trial, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- 411
- Enrollment target
NCT03789968 is a clinical trial that has completed, run by Thomas Jefferson University. The registered enrollment target is 411 participants.
The verdict
NCT03789968 has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- 411 participants
- Enrollment target
Study Summary
This study will assess changes in the incidence and severity of drug interactions before and after switching antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide-based regimens in treatment experienced patients living with HIV infection.
Interventions
- DRUG bictegravir/emtricitabine/tenofovir alafenamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 411 participants |
| Start Date | 2019-09-01 |
| Est. Completion | 2020-10-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03789968
The ClinicalTrials.gov registry entry for NCT03789968 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 411 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bictegravir/emtricitabine/tenofovir alafenamide is the first listed.
NCT03789968 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03789968 about?
NCT03789968 is a clinical study titled "The Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experienced Patients". This study will assess changes in the incidence and severity of drug interactions before and after switching antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide-based regimens in treatment experienced patients living with HIV infection.
What is the current status of trial NCT03789968?
This trial is currently completed. The enrollment target is 411 participants. The study started on 2019-09-01. Estimated completion is 2020-10-05.
What interventions are being tested in trial NCT03789968?
The interventions under investigation include: bictegravir/emtricitabine/tenofovir alafenamide (DRUG).
Who is sponsoring clinical trial NCT03789968?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.